How Multi-Cancer Blood Tests Are Changing Early Detection

Cancer screening is evolving beyond a single-organ approach to an approach that evaluates multiple organs throughout the entirety of the body with a simple blood test. In this episode, Dr. Michelle Beidelschies shares how Cancerguard can help health systems detect more cancers earlier, reduce late-stage diagnoses, and improve outcomes. We explore the clinical, operational, and financial implications of adopting multi-cancer early detection testing at scale. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice. The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.